Every article, presentation, spotlight, and news item we've tagged to Testing and Diagnostics.
Showing 25–48 of 157
Alnylam is implementing AI-enabled diagnostic pathways and clinical learning collaboratives to accelerate detection of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a progressive cardiac condition often diagnosed late. Earlier detection of this condition directly impacts treatment outcomes and disease trajectory, making systematic screening improvements clinically significant.
An artificial intelligence framework called interpretable adversarial decomposition learning (ADL) improves the clinical utility of Alzheimer's PET scans by filtering noise from disease signal, producing an ADAD score that correlates more closely with cognitive decline and neurodegeneration than traditional scoring methods. This advancement addresses a persistent gap between imaging findings and actual patient outcomes.
Syndex Bio's mcPCR technology preserves DNA methylation patterns during amplification, enabling detection of disease-associated epigenetic changes from minimal samples. This advance addresses a critical gap in early disease detection and biological age assessment, with implications spanning oncology, prenatal diagnostics, and longevity research.
Biograph's Executive Physical consolidates comprehensive cardiovascular, metabolic, cancer, and neurological screening into a single six-hour appointment using whole-body MRI, advanced CT, and biomarker analysis. This integrated approach identifies significant health findings in approximately 17 percent of participants and demonstrates measurable metabolic improvements in follow-up assessments.
AI-driven pattern recognition combined with expanded genomic sequencing and CRISPR gene editing is accelerating drug discovery and precision medicine by generating large datasets for machine learning models. This convergence enables shorter development cycles and more targeted therapeutic interventions based on individual genetic profiles.
Researchers mapped how living human brain cells coordinate structural changes across the lifespan, revealing that brain aging is an active, regulated biological process rather than passive deterioration. This represents the first large-scale analysis of living tissue, enabling identification of molecular targets for intervention in age-related neurological decline.
Human Longevity has launched a mobile application that consolidates clinical data, biomarkers, genetic information, and imaging results into a continuous health record accessible to users. The platform uses AI to identify patterns across longitudinal data, shifting preventive health assessment from episodic annual checkups to real-time risk monitoring and interpretation.
Curve Biosciences has developed AI-powered blood diagnostics that detect organ-specific disease signals by analyzing epigenetic markers in circulating DNA, validated in a 1,482-patient cirrhosis study. This approach shifts chronic disease monitoring from episodic snapshots to continuous molecular tracking of organ stress and aging progression.
Artificial intelligence is compressing drug discovery timelines from four to five years to approximately fourteen months by automating target identification, molecular design, and clinical trial prediction. This acceleration has direct implications for longevity therapeutics, where speed to market can determine whether interventions reach patients before age-related decline progresses beyond intervention points.
The Alzheimer's Drug Discovery Foundation has committed an additional $50 million to its Diagnostics Accelerator program, now totaling $150 million, to advance blood-based biomarkers, multi-marker panels, and AI-driven diagnostic tools for Alzheimer's disease. This investment targets earlier detection and disease monitoring to enable preventive interventions and combination therapies before irreversible neurodegeneration occurs.
GRAIL's cancer screening trial missed its primary composite endpoint, but subgroup analysis reveals meaningful detection rates in specific cancer types, indicating the technology may have clinical value despite the headline failure. Understanding what the data actually shows versus what was reported requires interpreting signal-to-noise in early detection research.
Chronic diseases develop through years of subtle, cumulative molecular drift before clinical diagnosis. The Buck Institute proposes longitudinal, AI-driven monitoring against individual baselines—treating each person as their own biological reference—to detect these early deviations rather than waiting for symptomatic presentation.
Abu Dhabi is establishing a large-scale health infrastructure combining genomic, phenotypic, and wearable data with AI to enable predictive care and accelerate drug discovery. This represents a shift toward population-level early detection and prevention rather than reactive treatment models.
Foodhak uses AI-driven personalization to translate nutrition science into daily food guidance aligned with individual health markers and goals. The approach positions food as preventive medicine rather than caloric constraint, addressing a systemic gap where most food choices optimize for taste and cost rather than long-term health outcomes.
Baseline immune cell profiles in older adults predict how their heart rate variability responds to acute exercise stress. This immune-autonomic relationship reveals why individuals show heterogeneous physiological resilience during aging, informing personalized intervention strategies.
Researchers developed a Mandarin-language cognitive toolkit to detect early Alzheimer's signs in older Chinese Americans, addressing diagnostic gaps created by language and cultural bias in English-based assessments. The validated tests correlate with English measures and early blood-based biomarkers, enabling earlier intervention and broader research participation in underserved communities.
Perplexity has launched an AI-powered health platform that aggregates fragmented health data from medical records, wearables, and provider systems into a unified dashboard, enabling personalized health insights grounded in individual biomarkers and trends. This addresses a critical infrastructure gap in longevity practice: the ability to contextualize health signals across time and across systems, moving beyond isolated data points toward pattern recognition that supports earlier intervention.
PREMAZ, a digital cognitive assessment tool, has partnered with Health is One to integrate early brain screening into everyday wellness services rather than clinical settings. The platform measures memory precision—the sharpness and reliability of recall—to detect subtle cognitive changes before decline becomes clinically apparent, shifting brain health assessment from reactive to preventive.
A systematic approach to lipid-lowering pharmacotherapy uses risk stratification and a six-step protocol to guide drug selection and escalation, optimizing cardiovascular protection across heterogeneous patient populations. This framework addresses the gap between guideline recommendations and individualized clinical decision-making in managing atherosclerotic cardiovascular disease risk.
AliveCor's Kardia 12L, an AI-powered portable 12-lead electrocardiogram system, has secured regulatory registration in Vietnam to enable hospital-grade cardiac diagnostics at point of care. The device reduces acquisition time by approximately 30% and simplifies electrode setup, allowing earlier detection of arrhythmias, myocardial infarction, and cardiac ischemia in community and outpatient settings.
Life Time is deploying SpiroFit, a cordless wearable metabolic testing system, across 190 clubs to measure VO2 max and fuel utilization during exercise. The technology generates personalized heart-rate training zones with lab-grade accuracy, enabling members to optimize training intensity and metabolic efficiency.
Researchers created a multi-tissue transcriptomic atlas across thirteen tissues in African turquoise killifish at six life stages, identifying molecular patterns of aging that vary by tissue type and sex. This resource establishes predictive biomarkers for aging dynamics and demonstrates how systemic and local factors drive age-related changes across the organism.
Insilico Medicine and Liquid AI are developing specialized AI foundation models to accelerate drug discovery by improving molecular prediction, biological activity forecasting, and compound design. This partnership demonstrates how computational efficiency in scientific AI can reduce timelines for therapeutic development while making tools accessible across the research community.
A two-year study of 958 adults aged 70+ found that daily multivitamin use slowed biological aging markers measured through epigenetic clocks, with the effect most pronounced in participants showing accelerated aging. While the slowdown was modest—measured in months rather than years—the consistent effect across multiple aging biomarkers suggests multivitamins may influence cellular-level processes relevant to healthspan rather than lifespan extension.
